110 related articles for article (PubMed ID: 8424397)
1. A phase II trial of vincristine in advanced or recurrent endometrial carcinoma. A Gynecologic Oncology Group Study.
Broun GO; Blessing JA; Eddy GL; Adelson MD
Am J Clin Oncol; 1993 Feb; 16(1):18-21. PubMed ID: 8424397
[TBL] [Abstract][Full Text] [Related]
2. Echinomycin in recurrent and metastatic endometrial carcinoma. A phase II trial of the Gynecologic Oncology Group.
Muss HB; Blessing JA; DuBeshter B
Am J Clin Oncol; 1993 Dec; 16(6):492-3. PubMed ID: 8256763
[TBL] [Abstract][Full Text] [Related]
3. A randomized comparison of doxorubicin alone versus doxorubicin plus cyclophosphamide in the management of advanced or recurrent endometrial carcinoma: A Gynecologic Oncology Group study.
Thigpen JT; Blessing JA; DiSaia PJ; Yordan E; Carson LF; Evers C
J Clin Oncol; 1994 Jul; 12(7):1408-14. PubMed ID: 8021731
[TBL] [Abstract][Full Text] [Related]
4. Phase II study of carboplatin in patients with advanced or recurrent endometrial carcinoma. A trial of the EORTC Gynaecological Cancer Group.
van Wijk FH; Lhommé C; Bolis G; Scotto di Palumbo V; Tumolo S; Nooij M; de Oliveira CF; Vermorken JB;
Eur J Cancer; 2003 Jan; 39(1):78-85. PubMed ID: 12504662
[TBL] [Abstract][Full Text] [Related]
5. Methotrexate in advanced endometrial carcinoma. A phase II trial of the Gynecologic Oncology Group.
Muss HB; Blessing JA; Hatch KD; Soper JT; Webster KD; Kemp GM
Am J Clin Oncol; 1990 Feb; 13(1):61-3. PubMed ID: 2407104
[TBL] [Abstract][Full Text] [Related]
6. Carboplatin, methotrexate and 5-fluorouracil in combination with medroxyprogesterone acetate (JMF-M) in the treatment of advanced or recurrent endometrial carcinoma: A Hellenic cooperative oncology group study.
Bafaloukos D; Aravantinos G; Samonis G; Katsifis G; Bakoyiannis C; Skarlos D; Kosmidis P
Oncology; 1999 Apr; 56(3):198-201. PubMed ID: 10202274
[TBL] [Abstract][Full Text] [Related]
7. A phase II trial of anastrozole in advanced recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study.
Rose PG; Brunetto VL; VanLe L; Bell J; Walker JL; Lee RB
Gynecol Oncol; 2000 Aug; 78(2):212-6. PubMed ID: 10926805
[TBL] [Abstract][Full Text] [Related]
8. Phase II trial of alternating courses of megestrol acetate and tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study.
Fiorica JV; Brunetto VL; Hanjani P; Lentz SS; Mannel R; Andersen W;
Gynecol Oncol; 2004 Jan; 92(1):10-4. PubMed ID: 14751131
[TBL] [Abstract][Full Text] [Related]
9. Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group.
Thigpen JT; Brady MF; Alvarez RD; Adelson MD; Homesley HD; Manetta A; Soper JT; Given FT
J Clin Oncol; 1999 Jun; 17(6):1736-44. PubMed ID: 10561210
[TBL] [Abstract][Full Text] [Related]
10. A phase II trial of arzoxifene, a selective estrogen response modulator, in patients with recurrent or advanced endometrial cancer.
McMeekin DS; Gordon A; Fowler J; Melemed A; Buller R; Burke T; Bloss J; Sabbatini P
Gynecol Oncol; 2003 Jul; 90(1):64-9. PubMed ID: 12821343
[TBL] [Abstract][Full Text] [Related]
11. A randomized, controlled phase III study of cyclophosphamide, doxorubicin, and vincristine with etoposide (CAV-E) or teniposide (CAV-T), followed by recombinant interferon-alpha maintenance therapy or observation, in small cell lung carcinoma patients with complete responses.
Tummarello D; Mari D; Graziano F; Isidori P; Cetto G; Pasini F; Santo A; Cellerino R
Cancer; 1997 Dec; 80(12):2222-9. PubMed ID: 9404698
[TBL] [Abstract][Full Text] [Related]
12. Vincristine with high-dose etoposide in advanced breast cancer: a phase II trial of the Piedmont Oncology Association.
Thomas GW; Muss HB; Jackson DV; McCulloch J; Ramseur W; McFarland J; Hoen H; Pavy M; Heath R
Cancer Chemother Pharmacol; 1994; 35(2):165-8. PubMed ID: 7987995
[TBL] [Abstract][Full Text] [Related]
13. Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a gynecologic oncology group study.
Thigpen JT; Brady MF; Homesley HD; Malfetano J; DuBeshter B; Burger RA; Liao S
J Clin Oncol; 2004 Oct; 22(19):3902-8. PubMed ID: 15459211
[TBL] [Abstract][Full Text] [Related]
14. Phase II trial of liposomal doxorubicin at 40 mg/m(2) every 4 weeks in endometrial carcinoma: a Gynecologic Oncology Group Study.
Homesley HD; Blessing JA; Sorosky J; Reid G; Look KY
Gynecol Oncol; 2005 Aug; 98(2):294-8. PubMed ID: 15975638
[TBL] [Abstract][Full Text] [Related]
15. A phase II trial of topotecan in patients with advanced, persistent, or recurrent endometrial carcinoma: a gynecologic oncology group study.
Miller DS; Blessing JA; Lentz SS; Waggoner SE
Gynecol Oncol; 2002 Dec; 87(3):247-51. PubMed ID: 12468321
[TBL] [Abstract][Full Text] [Related]
16. High-dose megestrol acetate in advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study.
Lentz SS; Brady MF; Major FJ; Reid GC; Soper JT
J Clin Oncol; 1996 Feb; 14(2):357-61. PubMed ID: 8636744
[TBL] [Abstract][Full Text] [Related]
17. Phase II trial of docetaxel in advanced or metastatic endometrial cancer: a Japanese Cooperative Study.
Katsumata N; Noda K; Nozawa S; Kitagawa R; Nishimura R; Yamaguchi S; Aoki D; Susumu N; Kuramoto H; Jobo T; Ueki K; Ueki M; Kohno I; Fujiwara K; Sohda Y; Eguchi F
Br J Cancer; 2005 Oct; 93(9):999-1004. PubMed ID: 16234823
[TBL] [Abstract][Full Text] [Related]
18. Dactinomycin in the treatment of recurrent or persistent endometrial carcinoma: A Phase II study of the Gynecologic Oncology Group.
Moore DH; Blessing JA; Dunton C; Buller RE; Reid GC
Gynecol Oncol; 1999 Dec; 75(3):473-5. PubMed ID: 10600310
[TBL] [Abstract][Full Text] [Related]
19. Ifosfamide treatment of recurrent or metastatic endometrial stromal sarcomas previously unexposed to chemotherapy: a study of the Gynecologic Oncology Group.
Sutton G; Blessing JA; Park R; DiSaia PJ; Rosenshein N
Obstet Gynecol; 1996 May; 87(5 Pt 1):747-50. PubMed ID: 8677079
[TBL] [Abstract][Full Text] [Related]
20. Phase II trial of the pegylated liposomal doxorubicin in previously treated metastatic endometrial cancer: a Gynecologic Oncology Group study.
Muggia FM; Blessing JA; Sorosky J; Reid GC
J Clin Oncol; 2002 May; 20(9):2360-4. PubMed ID: 11981008
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
